Switzerland-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has closed a private US$152m Series B financing and initiation of HEROIC, the company’s [...]
Switzerland: Vaderis Therapeutics closes US$152m Series B financing and initiates global Phase 3 clinical study
